US Patent

US8497256 — Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males

Method of Use · Assigned to Salix Pharmaceuticals Ltd · Expires 2031-06-23 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating male subjects with ulcerative colitis using 2-hydroxy-5-phenylazobenzoic acid derivatives.

USPTO Abstract

The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.

Drugs covered by this patent

balsalazide-disodium (BALSALAZIDE DISODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1229`	—	balsalazide-disodium

Patent Metadata

Patent number: US8497256
Jurisdiction: US
Classification: Method of Use
Expires: 2031-06-23
Drug substance claim: No
Drug product claim: No
Assignee: Salix Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.